Prostate Cancer Articles

Yu Previews Future of Castration-Naive Prostate Cancer
Evan Y. Yu, MD, discusses the available options for patients with metastatic castration-naïve prostate cancer.
Few Unanswered Questions Remain for Nonmetastatic Prostate Cancer
Harsha Ranganath, MD, discusses the current and future treatment of patients with nonmetastatic castration-resistant prostate cancer.
Radiation Oncologist Reflects on Traditional Treatment Modalities in Prostate Cancer
Holger L. Gieschen, MD, discusses the role of radiation therapy in prostate cancer and ongoing efforts to further refine this strategy.
Prostate Cancer Mortality Progress Stalls, Prompting Questions About PSA Policies
An analysis of prostate cancer trends adjusted for delays in reporting by stage of disease showed that incidence of late-stage disease increased from 2010 to 2014 after a decline in prostate-specific antigen use.
Daniel Vaena, MD, discusses the treatment of patients with metastatic castration-naïve disease and nonmetastatic castration-resistant prostate cancer, underscoring the importance of risk stratification in both settings.
Rucaparib Shows Encouraging Responses in BRCA+ mCRPC
Josep Piulats, MD, discussed the TRITON2 data and how rucaparib could shift treatment for these biomarker-specific patients with metastatic castration-resistant prostate cancer.
Radiotherapy Shows Benefit in Select Patients With Metastatic Prostate Cancer
Chris Parker, MD, discusses the clinical implications of STAMPEDE and how radiotherapy fits into the treatment paradigm for these patients.
Study Refines Racial Risk Stratification in Prostate Cancer
Walter Rayford, MD, PhD, MBA, discusses a race-based study in prostate cancer and how these results can drive treatment and diagnostic strategies.
Enzalutamide Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide plus androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival compared with ADT alone.
Enzalutamide/Radium-223 Combo Shows Potential in mCRPC
Benjamin L. Maughan, MD, PharmD, discusses the activity of the combination of radium-223 and enzalutamide in patients with metastatic castration-resistant prostate cancer.
Publication Bottom Border
Border Publication